NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$39.75 +0.05 (+0.13 %)
(As of 03/22/2019 03:57 AM ET)
Previous Close$39.70
Today's Range$39.46 - $40.29
52-Week Range$26.95 - $55.00
Volume349,400 shs
Average Volume642,155 shs
Market Capitalization$1.64 billion
P/E Ratio137.07
Dividend YieldN/A
Beta1.49
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a partnership with Thermo Fisher Scientific Pharma Services for the commercial production of EXPAREL. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$337.28 million
Cash Flow$0.9318 per share
Book Value$7.81 per share

Profitability

Net Income$-470,000.00

Miscellaneous

Employees518
Market Cap$1.64 billion
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) issued its quarterly earnings data on Thursday, February, 28th. The company reported $0.47 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.07 by $0.40. The company earned $95.12 million during the quarter, compared to analyst estimates of $93.69 million. Pacira Pharmaceuticals had a positive return on equity of 3.94% and a negative net margin of 0.14%. Pacira Pharmaceuticals's revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 earnings per share. View Pacira Pharmaceuticals' Earnings History.

When is Pacira Pharmaceuticals' next earnings date?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Pacira Pharmaceuticals.

What price target have analysts set for PCRX?

18 brokers have issued twelve-month price targets for Pacira Pharmaceuticals' shares. Their predictions range from $33.00 to $85.00. On average, they expect Pacira Pharmaceuticals' share price to reach $54.0667 in the next twelve months. This suggests a possible upside of 36.0% from the stock's current price. View Analyst Price Targets for Pacira Pharmaceuticals.

What is the consensus analysts' recommendation for Pacira Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 3 sell ratings, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Pacira's top line mainly comprises contribution from its marketed product Exparel. The company’s efforts to expand Exparel's label are encouraging. In April 2018, the FDA approved Exparel's label expansion to include administration via nerve block for prolonged regional analgesia. This is a positive for the company as it will further boost sales of Exparel. Pacira remains optimistic about its partnership with J&J to market and promote the use of Exparel with respective sales and medical education teams. Pacira’s agreement with China-based Nuance for the development and commercialization of Exparel in China is also an upside. Shares of Pacira have outperformed the industry in 2018. However, the company remains heavily dependent on Exparel for growth, which is concerning." (1/3/2019)
  • 2. Mizuho analysts commented, "We valued Pacira based on an equally weighted blend of discounted cash flow analysis and sum-of-the-parts valuation. This analysis generates our $43 price target, supporting our Neutral rating." (11/1/2018)
  • 3. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018)

Has Pacira Pharmaceuticals been receiving favorable news coverage?

Media stories about PCRX stock have been trending somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pacira Pharmaceuticals earned a news impact score of 1.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Pacira Pharmaceuticals' key competitors?

What other stocks do shareholders of Pacira Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Clovis Oncology (CLVS), Micron Technology (MU), Bausch Health Companies (BHC), ACADIA Pharmaceuticals (ACAD), Tesla (TSLA), Sangamo Therapeutics (SGMO), Netflix (NFLX) and Ionis Pharmaceuticals (IONS).

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:
  • Mr. David M. Stack, Chairman & CEO (Age 69)
  • Mr. Charles A. Reinhart III, C.P.A., M.B.A., Chief Financial Officer (Age 58)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)
  • Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 57)
  • Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 40)

Who are Pacira Pharmaceuticals' major shareholders?

Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (5.20%), Millennium Management LLC (2.98%), Baillie Gifford & Co. (2.27%), Polar Capital LLP (1.46%), Elk Creek Partners LLC (1.30%) and Partner Fund Management L.P. (1.27%). Company insiders that own Pacira Pharmaceuticals stock include Andreas Wicki, Charles A Reinhart III, David M Stack, Gary W Pace, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Which institutional investors are selling Pacira Pharmaceuticals stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Bank of New York Mellon Corp, Macquarie Group Ltd., Millennium Management LLC, Elk Creek Partners LLC, Castleark Management LLC, Canada Pension Plan Investment Board and United Services Automobile Association. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.

Which institutional investors are buying Pacira Pharmaceuticals stock?

PCRX stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Polar Capital LLP, D. E. Shaw & Co. Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Baillie Gifford & Co., Two Sigma Advisers LP and Two Sigma Investments LP. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Gary W Pace, Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy shares of Pacira Pharmaceuticals?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of PCRX stock can currently be purchased for approximately $39.75.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.64 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Pharmaceuticals employs 518 workers across the globe.

What is Pacira Pharmaceuticals' official website?

The official website for Pacira Pharmaceuticals is http://www.pacira.com.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  644 (Vote Outperform)
Underperform Votes:  452 (Vote Underperform)
Total Votes:  1,096
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: FAANG Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel